RSV Monoclonal Antibodies: Mechanisms of Action and How to Explain Them to Families

This episode dives into the immunological mechanisms of the two approved long-acting monoclonal antibodies and how to communicate their benefits clearly to parents. Dr. Tan first recaps the approved indications: both monoclonals are FDA-approved for infants under 8 months of age entering or born during their first RSV season whose mothers were either unvaccinated or vaccinated fewer than 14 days before delivery.

Dr. Creech then explains the science in accessible terms. He describes monoclonal antibodies as "filling an immunologic gas tank," distinct from vaccines — which act as flight simulators, training the immune system — and compares their waning protection to fuel running out in a car. The critical advance in these newer monoclonals is a modification to the Fc (tail) portion of the antibody — a so-called YTE modification — that dramatically extends the antibody's half-life from roughly one month to six, seven, or eight months. This single-dose, season-long protection is a paradigm shift. On the mechanistic side, one monoclonal targets Site 0 of the RSV fusion protein (exclusively pre-fusion), while the other targets Site 4 (both pre- and post-fusion). Despite these molecular differences, both are highly effective at coating the virus before it enters cells, preventing infection. Dr. Creech also notes that the success of these agents is likely to open the door to broader passive immunization strategies beyond RSV — for travelers, other respiratory pathogens, and potentially vaccine-hesitant populations.

In the next episode, "RSV Maternal Immunization vs. Monoclonal Antibodies: Comparing Immunity and Practical Differences," Dr. Simões and the panel compare the immunologic profiles of maternal vaccination and monoclonal antibody prophylaxis, including the role of breastfeeding.